Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vir Biotechnology, Inc.VIR · Entity 4522 | Chief Business Officer | April 01, 2021 | April 05, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vir Biotechnology, Inc.
Report date April 01, 2021 · Filed April 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,260 |
Ending reported balance
After 2021-04-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-04-01 · Exercise / conversion · Acquired 4,629 · Balance 13,889 Row 2 · 2021-04-01 · Exercise / conversion · Acquired 2,315 · Balance 16,204 Row 3 · 2021-04-01 · Sale · Disposed 6,944 · Balance 9,260 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.49 · Expires 2027-10-05 | Direct | 4,630 |
Reported balance
After 2021-04-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-04-01 · Exercise / conversion · Disposed 4,629 · Balance 4,630 F2: 1/4 of the shares subject to the stock option vested and became exercisable on April 3, 2018, and the remaining shares vest in 36 equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2028-07-19 | Direct | 37,037 |
Reported balance
After 2021-04-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-04-01 · Exercise / conversion · Disposed 2,315 · Balance 37,037 F3: 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020.
F2: 1/4 of the shares subject to the stock option vested and became exercisable on April 3, 2018, and the remaining shares vest in 36 equal monthly installments thereafter.
F3: 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2020 Filed May 15, 2020 23:18 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 75,000 | $30.05 | $2,253,885.00 |
DisclosureSEC source: 0001209191-20-029859 · doc4.xml · nonDerivative · entry 2 Parrish Jay · CIK 0001786372 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,222 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.0002 to $30.1521, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 14, 2020 Filed May 15, 2020 23:18 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 75,000 | $1.49 | $111,375.00 |
DisclosureSEC source: 0001209191-20-029859 · doc4.xml · nonDerivative · entry 1 Parrish Jay · CIK 0001786372 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2020 Filed Feb 12, 2021 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GiftCommon Stock | 106,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010195 · doc5.xml · nonDerivative · entry 2 Parrish Jay · CIK 0001786372 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,260 F2 · kind: Gift by the Reporting Person for estate planning purposes to an irrevocable trust which is managed by an independent trustee. The Reporting Person holds no voting or dispositive power over the securities held by the trust. Read SEC document |
| April 03, 2020 Filed Feb 12, 2021 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GiftCommon Stock | 106,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010195 · doc5.xml · nonDerivative · entry 1 Parrish Jay · CIK 0001786372 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,741 F1 · kind: Gift by the Reporting Person for estate planning purposes to an irrevocable trust which is managed by an independent trustee. The Reporting Person holds no voting or dispositive power over the securities held by the trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.